A bold funding initiative aims to help scientists predict a T cell’s target antigens, with implications far beyond cancer ...

The strong allogeneic response to donor MHC molecules in transplantation and the weak response to tumor antigens represent two important and divergent but potentially interactive immune responses.

To be effective in cancer immunotherapy, tumor antigens must be efficiently processed and presented to T cells by antigen-presenting cells (APCs), of which dendritic cells are considered to be the ...

Peptide-based vaccines deliver tumor-specific antigens to dendritic cells (DCs), triggering tumor-targeted T-cell responses. A peptide-peptide conjugate technology previously developed by researchers ...

As tumor cells divide, they accrue mutations that result in modified or novel peptide sequences that are unique to the cancer. Known as neoantigens, these tumor-specific proteins could be the key to ...

The firms hope to show that Verdi's off-the-shelf peptide cancer vaccine can shrink tumors and improve quality of life in patients with bone metastases.

Researchers and pediatric neurosurgeons at the University of Pittsburgh School of Medicine and UPMC Children's Hospital of ...

offering avenues for development of cancer-antigen peptide immunotherapy. "Ultimately, we hope for a future where clonal T ...

Researchers at the Icahn School of Medicine at Mount Sinai, led by Nina Bhardwaj, MD, Ph.D., Ward-Coleman Chair in Cancer ...

The majority of patients with acute myeloid leukemia (AML) under 60 years of age reach a complete hematological remission after intensive chemotherapy. However, only 20-40% of all patients with ...

Mayo Clinic researchers have discovered a new immunotherapy target, a cryptic antigen, that may be key in helping the immune system fight tumors in ovarian cancer. The study, published in Science ...